Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 15/20 | 0.71 |
| ▸ | AXL | P30530 | 3/20 | 0.71 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.63 |
| ▸ | CDK1 | P06493 | 3/20 | 0.63 |
| ▸ | ROS1 | P08922 | 3/20 | 0.63 |
| ▸ | FER | P16591 | 3/20 | 0.63 |
| ▸ | FLT4 | P35916 | 3/20 | 0.63 |
| ▸ | KDR | P35968 | 3/20 | 0.63 |
| ▸ | IRAK1 | P51617 | 3/20 | 0.63 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.63 |
| ▸ | PKN2 | Q16513 | 3/20 | 0.63 |
| ▸ | MARK2 | Q7KZI7 | 3/20 | 0.63 |
| ▸ | MINK1 | Q8N4C8 | 3/20 | 0.63 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.63 |
| ▸ | SLK | Q9H2G2 | 3/20 | 0.63 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.63 |
| ▸ | STK17A | Q9UEE5 | 3/20 | 0.63 |
| ▸ | MAP4K5 | Q9Y4K4 | 3/20 | 0.63 |
| ▸ | CDK7 | P50613 | 2/20 | 0.63 |
| ▸ | PLK4 | O00444 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13854148 | 0.87 | CDK8 (0.65) | CDK8AXLMAP4K4CDK1ROS1 | |
| SCHEMBL4831501 | 0.84 | CDK8 (0.81) | CDK8AXLMAP4K4CDK1ROS1 | |
| SCHEMBL413503 | 0.83 | RIPK1 (0.71) | CDK8AXLMAP4K4CDK1ROS1 | |
| SCHEMBL410704 | 0.83 | CDK8 (1.00) | CDK8AXLMAP4K4CDK1ROS1 | |
| SCHEMBL857125 | 0.83 | CDK8 (0.69) | CDK8AXLMAP4K4CDK1ROS1 | |
| SCHEMBL857038 | 0.83 | CDK8 (0.69) | CDK8AXLMAP4K4CDK1ROS1 | |
| SCHEMBL4165829 | 0.83 | RIPK1 (0.69) | CDK8AXLMAP4K4CDK1ROS1 | |
| SCHEMBL31064962 | 0.83 | RIPK1 (0.69) | CDK8AXLMAP4K4CDK1ROS1 | |
| SCHEMBL13854147 | 0.81 | RIPK1 (0.62) | CDK8AXLMAP4K4CDK1ROS1 | |
| SCHEMBL857265 | 0.80 | RIPK1 (0.57) | CDK8AXLMAP4K4CDK1ROS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633750-B1 | SYNTHESIS OF 5-SUBSTITUTED 7-AZAINDOLES AND 7-AZAINDOLINES | EISAI R&D MAN CO LTD (JP) | 2010-12-01 | — | — | EP | disclosed |
| EP-1490365-B1 | AZAINDOLES AS INHIBITORS OF C-JUN N-TERMINAL KINASES | EISAI R&D MAN CO LTD (JP) | 2010-02-10 | — | — | EP | disclosed |
| EP-1490365-B1 | AZAINDOLES AS INHIBITORS OF C-JUN N-TERMINAL KINASES | EISAI R&D MAN CO LTD (JP) | 2010-02-10 | — | — | EP | disclosed |
| US-7652137-B2 | Substitued azaindoline intermediate for use in the manufacture of 5-substituted 7-azaindolines and 5-substituted 7-azaindoles; pharmaceutical intermediates | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-01-26 | — | — | US | disclosed |
| US-20090306126-A1 | Indole Derivatives | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| CN-101448827-A | Indole derivatives | ASTRAZENECA AB (SE) | 2009-06-03 | — | — | CN | disclosed |
| US-7534800-B2 | 7-azaindoles as inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders | EISAI R & D DEVELOPMENT CO., LTD. (JP) | 2009-05-19 | — | — | US | disclosed |
| US-7534800-B2 | 7-azaindoles as inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders | EISAI R & D DEVELOPMENT CO., LTD. (JP) | 2009-05-19 | — | — | US | disclosed |
| US-7534800-B2 | 7-azaindoles as inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders | EISAI R & D DEVELOPMENT CO., LTD. (JP) | 2009-05-19 | — | — | US | disclosed |
| US-7291630-B2 | Azaindoles as inhibitors of c-Jun N-terminal kinases | EISAI CO., LTD. (JP) | 2007-11-06 | — | — | US | disclosed |
| US-7291630-B2 | Azaindoles as inhibitors of c-Jun N-terminal kinases | EISAI CO., LTD. (JP) | 2007-11-06 | — | — | US | disclosed |
| US-7291630-B2 | Azaindoles as inhibitors of c-Jun N-terminal kinases | EISAI CO., LTD. (JP) | 2007-11-06 | — | — | US | disclosed |
| EP-1490364-B1 | 7-AZAINDOLES AS INHIBITORS OF C-JUN N-TERMINAL KINASES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | EISAI R&D MAN CO LTD (JP) | 2007-09-26 | — | — | EP | disclosed |
| US-20060235042-A1 | Synthesis | EISAI CO., LTD. (JP) | 2006-10-19 | — | — | US | disclosed |
| US-20060111390-A1 | Azaindoles as inhibitors of c-jun n-terminal kinases | EISAI CO., LTD. (JP) | 2006-05-25 | — | — | US | disclosed |
| US-20050272761-A1 | 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders | EISAI CO., LTD. (JP) | 2005-12-08 | — | — | US | disclosed |
| EP-1490364-A1 | 7-AZAINDOLES AS INHIBITORS OF C-JUN N-TERMINAL KINASES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Eisai Co., Ltd. (JP) | 2004-12-29 | — | — | EP | disclosed |
| EP-1490365-A1 | AZAINDOLES AS INHIBITORS OF C-JUN N-TERMINAL KINASES | Eisai Co., Ltd. (JP) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003082868-A1 | 7-AZAINDOLES AS INHIBITORS OF C-JUN N-TERMINAL KINASES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | EISAI CO., LTD. (JP) | 2003-10-09 | — | — | WO | disclosed |
| WO-2003082869-A1 | AZAINDOLES AS INHIBITORS OF C-JUN N-TERMINAL KINASES | EISAI CO., LTD. (JP) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272761-A1 | 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders | API5, MAPKAPK5, MAP3K5 | CDK8 132/4885AXL 3108/4885MAP4K4 90/4885 |
| US-20060111390-A1 | Azaindoles as inhibitors of c-jun n-terminal kinases | API5, CDK5, AZI2 | CDK8 148/4885AXL 2369/4885MAP4K4 136/4885 |
| US-20060235042-A1 | Synthesis | AZI2, CYP3A5, CYP3A7 | CDK8 422/4885AXL 4652/4885MAP4K4 1772/4885 |
| US-20090306126-A1 | Indole Derivatives | MTOR, IDO1, AKT1S1 | CDK8 450/4885AXL 1246/4885MAP4K4 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.